ObsEva Presents Clinical Data on Oral GnRH Antagonist

ObsEva Presents Clinical Data on Oral GnRH Antagonist

-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological endocrinology 20th World Congress† GENEVA, Switzerland May 252022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the …

ObsEva Presents Clinical Data on Oral GnRH Antagonist Read More »